Cardiovascular disease is the world's number one killer angiotensin receptor blockers (ARBs) with diuretics, disease, responsible for one in every three deaths. As
ARBs with beta-blockers (BBs), centrally acting drugs per a report of the WHO, an estimated 17 million people with diuretics, and diuretics with diuretics. die of cardiovascular disease (CVD), particularly heart attack and stroke, every year. CVD is a group of The rationality of a FDC is the most controversial and disorders that includes heart disease (i.e., myocardial debated issue in today's clinical practice. Though there infarction and angina), stroke, hypertension, congestive are many advantages 5 of fixed-dose combinations, like heart failure (CHF), hardening of the arteries and other simplification of therapy, increased patient compliance, disorders of the circulatory system 1 . The presence of one reduction of total daily dose and adverse effects, disease is also associated with many more complications 2 .
reduction of overall cost of therapy, yet there are several disadvantages too. The use of FDCs can lead to There are several reasons leading to an increase in the polypharmacy, dose of one ingredient alone cannot be incidence of cardiovascular diseases. Clinical trials have altered, different pharmacokinetic properties can pose demonstrated that lack of patients' adherence 3 to therapy difficulty in frequency of administration and in case of is a major problem. Therefore, combination therapy using fixed-dose combinations (FDCs) with agents having complementary mechanism of action represents a new innovation that increases not only the patient adherence but also the effectiveness of treatment. Moreover, the seventh report of the Joint National Committee (JNC VII) on prevention, detection, evaluation and treatment of high blood pressure 4 has made a mention of combination therapy for the management of hypertension, viz., angiotensin converting enzyme inhibitors (ACEIs) with calcium channel blockers (CCBs), ACEIs with diuretics, *For correspondence E-mail: ptiwari@niper.ac.in development of an ADR, it is difficult to withdraw the suspected drug alone. Therefore, the risk-benefit assessment is essential before choosing a combination for therapy. The FDCs are of value only when they have been developed according to rational pharmacokinetic and pharmacodynamic criteria, and when claims for their benefits have been supported by evidence-based data and well-designed clinical studies. 13 . The assessment of rationality was These are well-known guidelines, which serve as performed by collecting evidences from published benchmark towards a rational FDC; based on these, the literature (in the open domain) about individual FDCs. criteria for this study were developed. These criteria Each FDC was assigned a score depending upon the include all the dimensions of defining a rational FDC, and match with the criteria. appropriate weighting (score) has been attached to each criterion. The total score thus obtained by a FDC will Altogether, 44 FDCs acting on the cardiovascular system reflect its standing on the scale; however, it is to be were studied. Table 1 lists all the FDCs with their noted that this score should not be viewed in isolation.
marketed strengths. Their availability in variable strengths provides flexibility in the titration of dosage. The first point in the seven-point criteria for evaluating the rationality of FDCs is that each active pharmaceutical
The results of the assessment showed that for ingredient (API) of the combination should preferably be approximately 40% of the FDCs, the individual in the essential medicine list (EML) of WHO or in the components were present in any one or both the EMLs. National List of Essential Medicines (NLEM) of India.
However, for over 50% of the FDCs, at least one Secondly, the dose of each API should meet the component was absent in both the EMLs, viz., requirements for a defined population group. The dose atorvastatin, lisinopril, ramipril, and clopidogrel. The doses and proportion of each API present in FDC should be used in the FDC matched with the recommended doses. appropriate for the intended use. Thirdly, the combination However, there was only one instance that merits should have the advantage of established evidence of discussion. The FDC of hydrochlorothiazide (HCTZ) and efficacy and safety over single compounds administered bisoprolol has HCTZ at a low dose, viz., 6.125 mg, separately in terms of its therapeutic efficacy and safety.
whereas the recommended dose is 12.5-50 mg/day. HCTZ+enalapril, the cost of the combination was found to be less than the added individual components' cost. Of the remaining 25 FDCs, the cost of individual components alone was not available in 9 FDCs. Therefore, it was not possible to assess the cost advantage of the FDC. But in some, it was observed that the cost of combination was as high as three times the total added cost of individual components (e.g., atenolol+nitrendipine).
The present study noted that for 19 FDCs there was published evidence on reduction in dose or adverse effects. Of these, in 18 cases the combination reduced the adverse effects of individual components. For example, in combining HCTZ with losartan, hypokalaemia caused by HCTZ is counterbalanced by losartan 16 . In only one instance, the published evidence showed reduction in dose and adverse effects. In the FDC of HCTZ+bisoprolol, HCTZ is effective in low dose, viz., 6.125 mg, and adverse effects like hypokalaemia, hyperuricemia are reduced in the FDC 17 . However, for 25 FDCs no published report was available regarding the reduction in dose or adverse effects. In the FDC of aspirin with clopidogrel, the risk of bleeding increases but the risk-benefit analysis showed that the benefit outweighs the risk of bleeding 18 .
The results of the present evaluation show similar PK properties of 37 FDCs. In 3 FDCs, even though the PK www.ijpsonline.com
properties were different, the individual components were combined as controlled-released form to overcome this problem. For example, in atenolol+nifedipine combination, nifedipine is given in a controlled-release form to increase its duration of action. In the FDC of clonidine+chlorthalidone, despite different PK properties, the published evidence suggested that this combination is effective as once-daily dosing 19 . All the FDCs had different mechanisms of action and as a result, they produced either additive or synergistic effects. For example, the combination of lisinopril and HCTZ was Drugs and Cosmetic Act, 1940, also takes a similar stand on this issue. The results of this study clearly demonstrate that in 33 FDCs (out of 44), the clinical evidence on safety and efficacy was established. However, for the remaining 11 combinations, no published evidence could be found. There were at least three cases in which limited numbers of trials have shown the safety and efficacy of a particular combination. For example, in the FDC of atenolol+amiloride+HCTZ, only one published evidence was found regarding the safety and efficacy of the combination in elderly patients 23 . Similar situations existed found to have synergistic effects 20, 21 .
for losartan+ramipril and propranolol+HCTZ. There seems to be an urgent need for clinical trials to These observations were used to assign a score to the substantiate the safety and efficacy of FDCs. FDC. Each criterion was awarded an appropriate weighting depending upon its relative contribution to the This study has made a systematic point-by-point evaluation rationality of the FDC. Therefore, the scoring criteria of fixed-dose combinations acting on the cardiovascular used in the study could award a maximum of 13 points to system, on the basis of the comprehensive criteria. An any FDC. It was found that 38 FDCs had scores above attempt has been made to use a system of scoring in the median score. Hence they were considered as relation to each FDC satisfying the criteria. A large rational combinations. Fig. 1 shows the distribution of majority of FDCs were found to comply with the criteria scores obtained by the FDCs. Two FDCs scored 13 developed for the assessment of rationality. However, points, which reflects a total match with the criteria for those that did not comply with the criteria could be the evaluating FDCs. Poor scoring of an FDC does offer subject of study by the clinicians and/or pharmaceutical scope for re-investigating the FDC for safety, efficacy, companies for assessing their clinical benefit. costs and adverse effects.
